Global Familial Amyloid Polyneuropathy Market Size By Type (FAP-I, FAP-II), By Application (Hospitals and Clinics, Others), By Region, And Segment Forecasts, 2023 to 2032

lobal Familial Amyloid Polyneuropathy Market Report Description

The Global Familial Amyloid Polyneuropathy (FAP) Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 3.2 billion by 2031, growing at a CAGR of 10.6% during the forecast period (2023–2031).

FAP is a rare, inherited, progressive disorder caused by abnormal amyloid protein deposition, leading to peripheral neuropathy and multi-organ damage. The market growth is primarily driven by increasing awareness about rare diseases, advancements in genetic testing and molecular diagnostics, and the availability of novel disease-modifying therapies. Additionally, rising investments in orphan drug development and favorable regulatory support are fueling the expansion of the FAP treatment landscape.

Market Drivers

Rising Awareness and Early Diagnosis

Growing awareness campaigns, improved screening programs, and enhanced access to genetic counseling are enabling early identification of FAP, thereby increasing patient access to available treatments.

Emergence of Novel Therapeutics

Disease-modifying drugs such as transthyretin (TTR) stabilizers and gene-silencing therapies have significantly improved patient outcomes, creating new opportunities in the market.

Orphan Drug Incentives and Regulatory Support

Regulatory agencies are offering fast-track approvals, extended market exclusivity, and financial incentives to pharmaceutical companies, encouraging investment in rare disease drug development.

Market Restraints

High Treatment Costs

FAP therapies are expensive due to their orphan drug status, making access challenging for patients in low- and middle-income countries.

Limited Awareness in Emerging Economies

Despite advancements, awareness and diagnosis remain low in certain regions, limiting market penetration.

Complex Disease Management

FAP requires a multidisciplinary approach involving neurologists, cardiologists, and genetic specialists, which can be logistically challenging and costly.

Market Opportunities

Expansion of Gene Therapy Platforms

The growing focus on RNA interference (RNAi)-based and CRISPR gene-editing therapies presents promising opportunities for disease-modifying treatments.

Growing Clinical Trials in Rare Diseases

Increased funding for rare disease research and a strong clinical pipeline of next-generation therapeutics are expected to accelerate market growth.

Penetration into Emerging Markets

Expansion of healthcare infrastructure and rising rare disease awareness in Asia-Pacific and Latin America could unlock new growth opportunities.

Market by Therapy Type Insights

Transthyretin Stabilizers accounted for the largest share in 2023 due to their proven efficacy in slowing disease progression.

Gene-Silencing Therapies (RNAi & ASO) are expected to witness the highest CAGR, driven by innovative RNA-based approaches that target the root cause of the disease.

Market by End-Use Insights

Hospitals & Specialty Clinics dominated the market in 2023 as they serve as primary centers for diagnosis, genetic testing, and treatment administration.

Research Institutes & Clinical Trials Centers are growing rapidly due to the surge in experimental therapies and ongoing R&D.

Market by Regional Insights

North America held the largest market share in 2023, supported by robust healthcare infrastructure, strong reimbursement frameworks, and high adoption of orphan drugs.

Europe remains a key region due to favorable regulatory pathways for rare diseases and well-established patient registries.

Asia-Pacific is expected to record the highest growth rate owing to rising healthcare investments, improving genetic diagnostics, and expanding awareness.

Competitive Scenario

Key players in the Global Familial Amyloid Polyneuropathy Market include:

Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Eidos Therapeutics, BridgeBio Pharma, Intellia Therapeutics, and Prothena Corporation.

These companies are focusing on RNA-based therapies, gene-editing technologies, strategic collaborations, and patient-support initiatives to expand their market presence.

Recent Developments:

2023: Alnylam Pharmaceuticals expanded access programs for patisiran (Onpattro) to new geographies.

2024: Pfizer received regulatory approval for a next-generation TTR stabilizer with improved safety and efficacy.

2025: Intellia Therapeutics advanced its in vivo CRISPR therapy for FAP into Phase II trials, marking a milestone in gene-editing therapies for rare diseases.

Scope of Work – Global Familial Amyloid Polyneuropathy Market

Key Market Developments

FDA & EMA approvals for novel TTR gene-silencing drugs are driving market expansion.

Multiple late-stage clinical trials for CRISPR-based therapies are reshaping the treatment landscape.

Collaborations between biotech companies and rare disease organizations are improving patient outreach and access.

FAQs

What is the current market size of the Global Familial Amyloid Polyneuropathy Market?

The market was valued at USD 1.4 billion in 2023.

What is the major growth driver of the Global Familial Amyloid Polyneuropathy Market?

The key driver is the availability of novel disease-modifying therapies and growing rare disease awareness.

Which is the largest region during the forecast period in the Global Familial Amyloid Polyneuropathy Market?

North America remains the largest region due to strong healthcare infrastructure and orphan drug incentives.

Which segment accounted for the largest market share in the Global Familial Amyloid Polyneuropathy Market?

Transthyretin Stabilizers held the largest market share in 2023.

Who are the key market players in the Global Familial Amyloid Polyneuropathy Market?

Major players include Alnylam Pharmaceuticals, Pfizer, Ionis Pharmaceuticals, and Intellia Therapeutics.

Would you like me to also create a visually appealing infographic summary of this market (with CAGR, key drivers, and leading players) for presentation purposes? Or should I generate similar reports for other rare disease markets for a complete portfolio?